Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445398 | 0.97 | NPSR1 (0.50) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| SCHEMBL17852 | 0.97 | NPSR1 (0.50) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| Hydrochloric Acid SCHEMBL27468145 | 0.95 | NPSR1 (0.48) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| SCHEMBL1928676 | 0.95 | — | — | |
| SCHEMBL25616531 | 0.92 | FFAR3 (0.50) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| SCHEMBL25616533 | 0.92 | FFAR3 (0.50) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| SCHEMBL8175853 | 0.92 | FFAR3 (0.50) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| SCHEMBL283125 | 0.92 | — | — | |
| SCHEMBL13881991 | 0.85 | NPSR1 (0.41) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 | |
| SCHEMBL17893326 | 0.85 | NPSR1 (0.43) | NPSR1FFAR3CYP4F2CYP4A11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-4376770-A | OXACEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1983-03-15 | — | — | US | claimed |
| JP-57154142-A | — | — | None | — | — | JP | disclosed |
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4550995-A2 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3492528-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543848-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA Pharmaceuticals Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119403782-A | Modulators of G protein-coupled receptor 88 | 阿卡蒂亚药品公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240188434-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-06-06 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0560613-A1 | Antimicrobial carbapenem derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| JP-S57154142-A | DIRECT SYNTHESIS OF TERTIARY CARBOXYLIC ACID ESTER | NIPPON SEIROU KK | 1982-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367143-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | GPR88, GPR84, GPR68 | NPSR1 262/4885FFAR3 330/4885CYP4F2 3842/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | NPSR1 1597/4885FFAR3 3901/4885CYP4F2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.